Table 2.
Associations between MLN, MLNR, SSTR2 and SSTR5 genotypes with the risk of biliary tract cancers and stones.
| Genotype |
Controls |
Biliary stonesa |
Biliary tract cancer |
||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) |
n (%) |
ORd (95% CI) |
Gallbladderb |
Bile ductc |
A.V.c |
||||
| n (%) | ORd (95% CI) | n (%) | ORd (95% CI) | n (%) | ORd (95% CI) | ||||
| MLN | 477 | 439 | 253 | 133 | 53 | ||||
| rs2281820 | |||||||||
| CC | 346 (77.6) | 317 (73.9) | 1.00 | 189 (74.7) | 1.00 | 94 (70.7) | 1.00 | 39 (75.0) | 1.00 |
| CT | 92 (20.6) | 107 (24.9) | 1.52 (1.06–2.18) | 62 (24.5) | 1.30 (0.89–1.90) | 37 (27.8) | 1.48 (0.94–2.33) | 13 (25.0) | 1.25 (0.63–2.45) |
| TT | 8 (1.8) | 5 (1.2) | 0.58 (0.18–1.82) | 2 (0.8) | – | 2 (1.5) | – | – | – |
| CT ± TT | 100 (22.4) | 112 (26.1) | 1.42 (1.00–2.00) | 64 (25.3) | 1.23 (0.85–1.79) | 39 (29.3) | 1.42 (0.91–2.21) | 13 (25.0) | 1.13 (0.57–2.20) |
| P trend | 0.03 | 0.20 | 0.09 | 0.59 | |||||
| Rs3793079 | |||||||||
| AA | 295 (66.1) | 246 (57.3) | 1.00 | 162 (64.0) | 1.00 | 75 (56.4) | 1.00 | 32 (61.5) | 1.00 |
| AT | 135 (30.3) | 166 (38.7) | 1.64 (1.20–2.25) | 80 (31.6) | 1.08 (0.77–1.53) | 54 (40.6) | 1.58 (1.04–2.38) | 18 (34.6) | 1.19 (0.64–2.21) |
| TT | 16 (3.6) | 17 (4.0) | 1.15 (0.55–2.38) | 11 (4.4) | 1.26 (0.56–2.80) | 4 (3.0) | – | 2 (3.9) | – |
| AT ± TT | 151 (33.9) | 183 (42.7) | 1.58 (1.17–2.13) | 91 (36.0) | 1.10 (0.79–1.54) | 58 (43.6) | 1.49 (1.00–2.23) | 20 (38.5) | 1.18 (0.65–2.14) |
| P trend | 0.002 | 0.62 | 0.03 | 0.58 | |||||
| Rs2281819 | |||||||||
| AA | 343 (76.9) | 315 (73.4) | 1.00 | 181 (71.5) | 1.00 | 95 (71.4) | 1.00 | 40 (76.9) | 1.00 |
| AT | 99 (22.2) | 108 (25.2) | 1.34 (0.95–1.90) | 71 (28.1) | 1.39 (0.97–2.01) | 36 (27.1) | 1.31 (0.83–2.05) | 11 (21.2) | 0.90 (0.44–1.83) |
| TT | 4 (0.9) | 6 (1.4) | – | 1 (0.4) | – | 2 (1.5) | – | 1 (1.9) | – |
| AT ± TT | 103 (23.1) | 114 (26.6) | 1.33 (0.95–1.87) | 72 (28.5) | 1.35 (0.94–1.94) | 38 (28.6) | 1.32 (0.85–2.06) | 12 (23.1) | 0.95 (0.48–1.88) |
| P trend | 0.10 | 0.08 | 0.23 | 0.81 | |||||
| MLNR | |||||||||
| Rs9568169 | |||||||||
| CC | 151 (33.9) | 129 (30.1) | 1.00 | 89 (35.2) | 1.00 | 54 (40.6) | 1.00 | 19 (36.5) | 1.00 |
| CA | 199 (44.6) | 212 (49.5) | 1.30 (0.93–1.81) | 115 (45.4) | 1.00 (0.70–1.42) | 61 (45.9) | 0.86 (056–1.32) | 25 (48.1) | 1.00 (0.53–1.90) |
| AA | 96 (21.5) | 87 (20.3) | 1.29 (0.85–1.95) | 49 (19.4) | 0.95 (0.61–1.48) | 18 (13.5) | 0.49 (0.27–0.89) | 8 (15.4) | 0.59 (0.25–1.41) |
| CA ± AA | 295 (66.1) | 299 (69.9) | 1.30 (0.95–1.77) | 164 (64.8) | 0.98 (0.71–1.37) | 79 (59.4) | 0.73 (0.49–1.10) | 33 (63.5) | 0.86 (0.47–1.57) |
| P trend | 0.13 | 1.00 | 0.56 | 0.93 | |||||
| SSTR2 | |||||||||
| Rs7210080 | |||||||||
| TT | 230 (51.6) | 215 (50.1) | 1.00 | 117 (46.2) | 1.00 | 75 (56.4) | 1.00 | 28 (53.9) | 1.00 |
| TC | 176 (39.4) | 183 (42.7) | 1.04 (0.77–1.41) | 112 (44.3) | 1.25 (0.90–1.74) | 47 (35.3) | 0.82 (0.54–1.25) | 17 (32.7) | 0.78 (0.41–1.48) |
| CC | 40 (9.0) | 31 (7.2) | 0.70 (0.41–1.20) | 24 (9.5) | 1.12 (0.64–1.97) | 11 (8.3) | 0.83 (0.40–1.71) | 7 (13.4) | 1.50 (0.61–3.70) |
| TC + CC | 216 (48.4) | 214 (49.9) | 0.97 (0.73–1.30) | 136 (53.8) | 1.23 (0.89–1.68) | 58 (43.6) | 0.82 (0.55–1.22) | 24 (46.1) | 0.91 (0.51–1.62) |
| P trend | 0.84 | 0.19 | 0.35 | 0.49 | |||||
| Rs1466113 | |||||||||
| GG | 121 (27.1) | 112 (26.1) | 1.00 | 76 (30.0) | 1.00 | 34 (25.6) | 1.00 | 16 (30.8) | 1.00 |
| GC | 240 (53.8) | 221 (51.5) | 1.08 (0.76–1.51) | 120 (47.5) | 0.83 (0.58–1.20) | 65 (48.9) | 0.96 (0.60–1.55) | 18 (34.6) | 0.53 (0.26–1.09) |
| CC | 85 (19.1) | 96 (22.4) | 1.31 (0.85–2.01) | 57 (22.5) | 1.12 (0.71–1.75) | 34 (25.5) | 1.46 (0.84–2.56) | 18 (34.6) | 1.63 (0.78–3.41) |
| GC + CC | 325 (72.9) | 317 (73.9) | 1.14 (0.82–1.57) | 177 (70.0) | 0.91 (0.64–1.28) | 99 (74.4) | 1.09 (0.70–1.71) | 36 (69.2) | 0.81 (0.43–1.52) |
| P trend | 0.82 | 0.26 | 0.69 | 0.05 | |||||
| Rs2236748 | |||||||||
| GG | 304 (68.2) | 315 (73.6) | 1.00 | 185 (73.1) | 1.00 | 92 (69.2) | 1.00 | 42 (80.8) | 1.00 |
| GA | 126 (28.2) | 108 (25.2) | 0.91 (0.65–1.27) | 64 (25.3) | 0.83 (0.58–1.20) | 38 (28.6) | 1.02 (0.66–1.59) | 10 (19.2) | 0.58 (0.28–1.20) |
| AA | 16 (3.6) | 5 (1.2) | – | 4 (1.6) | – | 3 (2.2) | – | – | – |
| GA + AA | 142 (31.8) | 114 (26.4) | 0.83 (0.61–1.15) | 68 (26.9) | 0.79 (0.55–1.12) | 41 (30.8) | 0.97 (0.63–1.48) | 10 (19.2) | 0.51 (0.25–1.06) |
| P trend | 0.45 | 0.27 | 0.98 | ||||||
| Rs2236750 | |||||||||
| GG | 122 (27.5) | 138 (32.2) | 1.00 | 73 (28.9) | 1.00 | 47 (35.3) | 1.00 | 21 (40.4) | 1.00 |
| GA | 231 (52.0) | 214 (49.9) | 0.78 (0.56–1.10) | 124 (49.0) | 0.92 (0.63–1.33) | 62 (46.6) | 0.67 (0.43–1.05) | 21 (40.4) | 0.49 (0.26–0.94) |
| AA | 91 (20.5) | 77 (17.9) | 0.70 (0.46–1.07) | 56 (22.1) | 1.00 (0.64–1.57) | 24 (18.1) | 0.68 (0.38–1.20) | 10 (19.2) | 0.65 (0.29–1.46) |
| GA + AA | 322 (72.5) | 291 (67.8) | 0.76 (0.55–1.05) | 180 (71.1) | 0.94 (0.66–1.34) | 86 (64.7) | 0.67 (0.44–1.02) | 31 (59.6) | 0.53 (0.29–0.97) |
| P trend | 0.20 | 0.63 | 0.09 | 0.03 | |||||
| SSTR5 | |||||||||
| Rs169068 | |||||||||
| TT | 268 (60.2) | 259 (61.5) | 1.00 | 160 (63.5) | 1.00 | 79 (59.4) | 1.00 | 28 (53.9) | 1.00 |
| TC | 157 (35.3) | 145 (34.4) | 0.91 (0.67–1.24) | 80 (31.7) | 0.82 (0.59–1.15) | 41 (30.8) | 0.92 (0.60–1.42) | 21 (40.4) | 1.29 (0.71–2.37) |
| CC | 20 (4.5) | 17 (4.0) | 1.02 (0.49–2.13) | 12 (4.8) | 0.95 (0.44–2.05) | 13 (9.8) | 2.40 (1.13–5.13) | 3 (5.8) | – |
| TC + CC | 177 (39.8) | 162 (38.5) | 0.92 (0.69–1.24) | 92 (36.5) | 0.84 (0.60–1.16) | 54 (40.6) | 1.08 (0.72–1.62) | 24 (46.1) | 1.32 (0.74–2.37) |
| P trend | 0.57 | 0.26 | 0.84 | 0.39 | |||||
OR, odds ratio; 95% CI, 95% confidence interval.
Test of trend for the number of copies of the variant allele (0, 1 and 2).
Did not calculate OR when N was less than 5.
Biliary stone (gallstone and bile duct stone) cases were compared to controls without biliary stones (n = 341).
Gallbadder cancer cases were compared with population controls who never had a cholecystectomy (n = 422).
Bile duct and ampulla of Vater cancer cases were compared with all population controls (n = 447).
Adjusted for age and gender.